Supportive Care in Cancer

, Volume 21, Issue 2, pp 549–555 | Cite as

Taste alteration in breast cancer patients treated with taxane chemotherapy: experience, effect, and coping strategies

  • Rebecca M. SpeckEmail author
  • Angela DeMichele
  • John T. Farrar
  • Sean Hennessy
  • Jun J. Mao
  • Margaret G. Stineman
  • Frances K. Barg
Original Article



This study examined the experience and coping strategies for taste alteration in female breast cancer patients treated with docetaxel or paclitaxel.


A purposive sample of 25 patients currently receiving docetaxel or paclitaxel or within 6 months of having completed treatment was recruited. Semi-structured interviews and patient-level data were utilized for this exploratory descriptive study. Interview data were analyzed with the constant comparative method; patient-level data were abstracted from the electronic medical record.


Of all side effects reported from taxanes, the most common was taste alteration (8 of 10 docetaxel patients, 3 of 15 paclitaxel patients). Women that experience taste alteration chose not to eat as much, ate on an irregular schedule, and/or lost interest in preparing meals for themselves and/or their family. Women adopted a variety of new behaviors to deal with the taste alteration and its effects, including trying new recipes, eating strongly flavored foods, honoring specific food cravings, eating candy before meals, cutting food with lemon, drinking sweetened drinks, using plastic eating utensils, drinking from a straw, brushing their teeth and tongue before meals, and using baking soda and salt wash or antibacterial mouthwash.


Taste alteration affects breast cancer patients’ lives, and they develop management strategies to deal with the effect. While some self-management strategies can be seen as positively adaptive, the potential for increased caloric consumption and poor eating behaviors associated with some coping strategies may be a cause for concern given the observation of weight gain during breast cancer treatment and association of obesity with poor treatment outcomes in breast cancer patients. Further studies are warranted to determine the overall burden of this symptom and measurement of cancer and non-cancer-related consequences of these behavioral adaptations.


Chemotherapy Breast cancer Taste Dysgeusia 


Conflicts of interest

The authors declare they have no conflict of interest to report in relationship to this manuscript.


  1. 1.
    Comeau TB, Epstein JB, Migas C (2001) Taste and smell dysfunction in patients receiving chemotherapy: a review of current knowledge. Support Care Cancer 9:575–580PubMedCrossRefGoogle Scholar
  2. 2.
    Hong JH, Omur-Ozbek P, Stanek BT et al (2009) Taste and odor abnormalities in cancer patients. J Support Oncol 7:58–65PubMedGoogle Scholar
  3. 3.
    Hovan AJ, Williams PM, Stevenson-Moore P et al (2010) A systematic review of dysgeusia induced by cancer therapies. Support Care Cancer 18:1081–1087PubMedCrossRefGoogle Scholar
  4. 4.
    Berteretche MV, Dalix AM, d'Ornano AM et al (2004) Decreased taste sensitivity in cancer patients under chemotherapy. Support Care Cancer 12:571–576PubMedCrossRefGoogle Scholar
  5. 5.
    Mattsson T, Arvidson K, Heimdahl A et al (1992) Alterations in taste acuity associated with allogeneic bone marrow transplantation. J Oral Pathol Med 21:33–37PubMedCrossRefGoogle Scholar
  6. 6.
    Mulder NH, Smit JM, Kreumer WM et al (1983) Effect of chemotherapy on taste sensation in patients with disseminated malignant melanoma. Oncology 40:36–38PubMedCrossRefGoogle Scholar
  7. 7.
    Steinbach S, Hummel T, Bohner C et al (2009) Qualitative and quantitative assessment of taste and smell changes in patients undergoing chemotherapy for breast cancer or gynecologic malignancies. J Clin Oncol 27:1899–1905PubMedCrossRefGoogle Scholar
  8. 8.
    Sanchez-Lara K, Sosa-Sanchez R, Green-Renner D et al (2010) Influence of taste disorders on dietary behaviors in cancer patients under chemotherapy. Nutr J 9:15PubMedCrossRefGoogle Scholar
  9. 9.
    Epstein JB, Phillips N, Parry J et al (2002) Quality of life, taste, olfactory and oral function following high-dose chemotherapy and allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 30:785–792PubMedCrossRefGoogle Scholar
  10. 10.
    Rhodes VA, McDaniel RW, Hanson B et al (1994) Sensory perception of patients on selected antineoplastic chemotherapy protocols. Cancer Nurs 17:45–51PubMedCrossRefGoogle Scholar
  11. 11.
    Zabernigg A, Gamper EM, Giesinger JM et al (2010) Taste alterations in cancer patients receiving chemotherapy: a neglected side effect? Oncologist 15:913–920PubMedCrossRefGoogle Scholar
  12. 12.
    Bernhardson BM, Tishelman C, Rutqvist LE (2008) Self-reported taste and smell changes during cancer chemotherapy. Support Care Cancer 16:275–283PubMedCrossRefGoogle Scholar
  13. 13.
    Jensen SB, Mouridsen HT, Bergmann OJ et al (2008) Oral mucosal lesions, microbial changes, and taste disturbances induced by adjuvant chemotherapy in breast cancer patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 106:217–226PubMedCrossRefGoogle Scholar
  14. 14.
    Bernhardson BM, Tishelman C, Rutqvist LE (2007) Chemosensory changes experienced by patients undergoing cancer chemotherapy: a qualitative interview study. J Pain Symptom Manag 34:403–412CrossRefGoogle Scholar
  15. 15.
    Rehwaldt M, Wickham R, Purl S et al (2009) Self-care strategies to cope with taste changes after chemotherapy. Oncol Nurs Forum 36:E47–E56PubMedCrossRefGoogle Scholar
  16. 16.
    Bernhardson BM, Tishelman C, Rutqvist LE (2009) Taste and smell changes in patients receiving cancer chemotherapy—distress, impact on daily life, and self-care strategies. Cancer Nurs 32:45–54PubMedCrossRefGoogle Scholar
  17. 17.
    Maxwell J (1997) Designing a qualitative study. In: Bickman L, Rog DJ (eds) Handbook of applied social research methods. Sage, Thousand Oaks, pp 69–100Google Scholar
  18. 18.
    Patton M (2002) Qualitative research and evaluation methods. Sage, LondonGoogle Scholar
  19. 19.
    Speck RM, Demichele A, Farrar JT, et al. (2012) Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients. Support Care Cancer Jan 11 [Epub ahead of print]Google Scholar
  20. 20.
    QSR International (2008) Nvivo qualitative data analysis software, (ed version 8). QSR International Pty LtdGoogle Scholar
  21. 21.
    Boeije H (2002) A purposeful approach to the constant comparative method in the analysis of qualitative interviews. Qual Quant 36:391–409CrossRefGoogle Scholar
  22. 22.
    Velos I (2011) Velos eResearch. Velos, Inc., FremontGoogle Scholar
  23. 23.
    Macquart-Moulin G, Viens P, Palangie T et al (2000) High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: does impact on quality of life jeopardize feasibility and acceptability of treatment? J Clin Oncol 18:754–764PubMedGoogle Scholar
  24. 24.
    Heasman KZ, Sutherland HJ, Campbell JA et al (1985) Weight gain during adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 5:195–200PubMedCrossRefGoogle Scholar
  25. 25.
    Hernandez BM, Bonomi P, Hoeltgen T (1983) Weight gain during adjuvant chemotherapy for stage II breast cancer. Proc Am Soc Clin Oncol 2:108Google Scholar
  26. 26.
    Foltz AT (1985) Weight gain among stage II breast cancer patients: a study of five factors. Oncol Nurs Forum 12:21–26PubMedGoogle Scholar
  27. 27.
    Chlebowski RT, Aiello E, McTiernan A (2002) Weight loss in breast cancer patient management. J Clin Oncol 20:1128–1143PubMedCrossRefGoogle Scholar
  28. 28.
    Loi S, Milne RL, Friedlander ML et al (2005) Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 14:1686–1691PubMedCrossRefGoogle Scholar
  29. 29.
    Janni JW, Hepp PGM, Andergassen U et al (2011) Final multivariate analysis of obesity and survival in patients with node-positive primary breast cancer: the ADEBAR trial. J Clin Oncol 29:abstr 1020Google Scholar
  30. 30.
    Gluz O, Liedtke C, Kates RE et al (2011) Molecular subtypes, body mass index (BMI), and their time-varying prognostic impact in node-positive breast cancer (BC): pooled analysis from the WSG AM-01 and -02 trials. J Clin Oncol 29:abstr 1021Google Scholar
  31. 31.
    Hepp PGM, Rack B, Annecke K, et al. (2010) Multivariate analysis of obesity and disease free survival in patients with nodal positive primary breast cancer—the ADEBAR Trial. San Antonio Breast Cancer Symposium, 2010. Accessed 3 March 2012
  32. 32.
    Berclaz G, Li S, Price KN et al (2004) Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol 15:875–884PubMedCrossRefGoogle Scholar
  33. 33.
    de Azambuja E, McCaskill-Stevens W, Francis P et al (2010) The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Breast Cancer Res Treat 119:145–153PubMedCrossRefGoogle Scholar
  34. 34.
    Sparano JA, Wang M, Martino S, et al. (2010) Obesity at diagnosis is associated with inferior outcomes in hormone receptor positive breast cancer. San Antonio Breast Cancer Symp, 2010: abstr S2-1Google Scholar
  35. 35.
    Heckmann JG, Heckmann SM, Lang CJ et al (2003) Neurological aspects of taste disorders. Arch Neurol 60:667–671PubMedCrossRefGoogle Scholar
  36. 36.
    Fan G, Filipczak L, Chow E (2007) Symptom clusters in cancer patients: a review of the literature. Curr Oncol 14:173–179PubMedCrossRefGoogle Scholar
  37. 37.
    National Cancer Institute (2009) Common terminology criteria for adverse events v4.0. NCI, NIH, DHHS. Accessed 10 August 2011
  38. 38.
    Wickham RS, Rehwaldt M, Kefer C et al (1999) Taste changes experienced by patients receiving chemotherapy. Oncol Nurs Forum 26:697–706PubMedGoogle Scholar
  39. 39.
    Cella D, Peterman A, Hudgens S et al (2003) Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane). Cancer 98:822–831PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Rebecca M. Speck
    • 1
    • 2
    Email author
  • Angela DeMichele
    • 1
    • 3
  • John T. Farrar
    • 1
    • 2
  • Sean Hennessy
    • 1
  • Jun J. Mao
    • 4
  • Margaret G. Stineman
    • 1
    • 5
  • Frances K. Barg
    • 4
  1. 1.Department of Biostatistics and Epidemiology, Perelman School of MedicineUniversity of PennsylvaniaPhiladelphiaUSA
  2. 2.Department of Anesthesiology and Critical Care, Perelman School of MedicineUniversity of PennsylvaniaPhiladelphiaUSA
  3. 3.Division of Hematology and Oncology, Perelman School of MedicineUniversity of PennsylvaniaPhiladelphiaUSA
  4. 4.Department of Family Medicine and Community Health, Perelman School of MedicineUniversity of PennsylvaniaPhiladelphiaUSA
  5. 5.Department of Physical Medicine and Rehabilitation, Perelman School of MedicineUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations